大佬們最新重倉股來了!
公募基金一季度規模再創新高,達28.81萬億,環比增長5.66%

ETF市場規模再創新高,達2.39萬億元,環比增長16.96%,非貨幣ETF規模突破2萬億元。

公募基金重倉A股中,貴州茅台穩坐重倉股第一,重倉股市值達1469.68億元。第二名寧德時代,重倉市值1104.69億元。

A股增持前三為寧德時代、紫金礦業和美的集團,增持市值分別為292.56億元、215.22億元、以及146.37億元;減持前三位藥明康德、卓勝微和智飛生物。

港股重倉持股方面,前三的股票分別騰訊控股、美團-W以及中國海洋石油。



明星基金經理重倉股一覽:


























Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.